Stellantis cancels Ram 1500 electric pickup citing weak demand
Investing.com - H.C. Wainwright has reiterated a Buy rating and $42.00 price target on Anavex Life Sciences (NASDAQ:AVXL) following new clinical data from its Phase 2b/3 trial of blarcamesine in Alzheimer’s disease. Currently trading at $8.88, the stock shows significant upside potential according to analyst consensus, with targets ranging from $15 to $46. InvestingPro analysis indicates the stock is currently overvalued relative to its Fair Value.
The data, reported on September 9, showed that after 48 weeks, early Alzheimer’s patients in the defined Precision Medicine population ABCLEAR3 taking 30mg once-daily oral blarcamesine demonstrated minimal decline across standard measurement scales. Despite the promising clinical results, InvestingPro data shows the company maintains strong financial health with a current ratio of 8.93 and holds more cash than debt on its balance sheet.
For the ADAS-Cog13 test, blarcamesine showed a 48-week change from baseline of 0.853, compared to approximately 1 point typical annual decline in prodromal aging adults, representing an 84.7% reduction in decline versus placebo.
The CDR-SB test showed a change from baseline of 0.465 with blarcamesine, aligning with the 0-0.5 point annual range typically seen in prodromal aging, despite the more advanced baseline stage of Alzheimer’s impairment in the study population.
The results indicate that oral blarcamesine treatment over 48 weeks in a precision medicine-defined patient group with non-mutated SIGMAR1, which includes up to approximately 70% of the global population, can shift cognitive decline patterns of mild cognitive impairment or mild Alzheimer’s patients to resemble those of prodromal Alzheimer’s patients. For deeper insights into AVXL’s financial health, valuation metrics, and 8 additional ProTips, access the comprehensive Pro Research Report available exclusively on InvestingPro.
In other recent news, Anavex Life Sciences reported its financial results for the third quarter of 2025, revealing a net loss of $13.2 million, or $0.16 per share. This figure slightly missed analysts’ expectations, which projected an EPS of -$0.1457. Despite the earnings miss, the company maintains a strong cash position of $101.2 million with no debt. Additionally, H.C. Wainwright has reiterated a Buy rating on Anavex Life Sciences, setting a price target of $42.00. This follows the publication of a peer-reviewed study highlighting the benefits of Anavex’s compound blarcamesine. The study, published in Neuroscience Letters, demonstrated that blarcamesine prevented memory impairment and brain oxidative injury in an Alzheimer’s disease model. These developments provide important insights into the company’s financial health and ongoing research efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.